Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 11/20 | 0.47 |
| ▸ | CTSD | P07339 | 5/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9823763 | 1.00 | REN (0.47) | RENCTSDMETAP2EPHX1CPB2 | |
| SCHEMBL14415381 | 1.00 | REN (0.47) | RENCTSDMETAP2EPHX1CPB2 | |
| Hydrochloric Acid SCHEMBL9831215 | 0.99 | REN (0.46) | RENCTSDMETAP2EPHX1CPB2 | |
| SCHEMBL7355979 | 0.88 | REN (0.48) | RENCTSDMETAP2CPB2MMP8 | |
| Hydrochloric Acid SCHEMBL7385221 | 0.87 | REN (0.47) | RENCTSDMETAP2CPB2MMP8 | |
| Hydrochloric Acid SCHEMBL9832917 | 0.87 | REN (0.47) | RENCTSDMETAP2CPB2MMP8 | |
| SCHEMBL7270757 | 0.84 | REN (0.51) | RENCTSDMETAP2EPHX1CPB2 | |
| SCHEMBL7270755 | 0.84 | REN (0.51) | RENCTSDMETAP2EPHX1CPB2 | |
| Hydrochloric Acid SCHEMBL9831459 | 0.83 | REN (0.44) | RENMETAP2 | |
| SCHEMBL9832436 | 0.80 | METAP2 (0.44) | RENCTSDMETAP2EPHX1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070207952-A1 | Long Acting Biologically Active Conjugates | SEQUOIA PHARMACEUTICALS (US) | 2007-09-06 | — | — | US | disclosed |
| US-5164388-A | Hypotensive agents, treatment of congestive heart failure | ABBOTT LABORATORIES (US) | 1992-11-17 | — | — | US | disclosed |
| EP-0439556-A1 | HETEROCYCLIC PEPTIDE RENIN INHIBITORS | ABBOTT LABORATORIES (US) | 1991-08-07 | — | — | EP | disclosed |
| WO-1990004917-A1 | HETEROCYCLIC PEPTIDE RENIN INHIBITORS | ABBOTT LABORATORIES (US) | 1990-05-17 | — | — | WO | disclosed |
| EP-0365992-A1 | Heterocyclic peptide renin inhibitors | ABBOTT LABORATORIES (US) | 1990-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207952-A1 | Long Acting Biologically Active Conjugates | ALB, ACE, VIP | REN 5/4885CTSD 415/4885METAP2 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.